Epidermal growth factor receptor (EGFR) mutation is one of the key oncogenic mutations in
non-small-cell lung cancer with adenocarcinoma histology. Exon 19 deletions and exon 21 …

Brain metastases are common intracranial neoplasms and their frequency increases with
prolonged survival of cancer patients. New pharmaceuticals targeting oncogenic kinases …

Introduction Although frequent in NSCLC, patients with brain metastases (BMs) are often
excluded from immune checkpoint inhibitor (ICI) trials. We evaluated BM outcome in a less …

Objectives Brain metastases are common among patients with non-squamous non-small-
cell lung cancer (NSCLC) and result in a poor prognosis. Consequently, such patients are …

The functions of immune cells in brain metastases are unclear because the brain has
traditionally been considered “immune privileged.” However, we found that a subgroup of …

Immunotherapies against brain metastases have shown clinical benefits when applied to
asymptomatic patients, but they are largely ineffective in symptomatic cases for unknown …

The diagnosis of brain metastases has historically been a dreaded, end-stage complication
of systemic disease. Additionally, with the increasing effectiveness of systemic therapies that …

Lung cancer is one of the deadliest cancers, in which non-small cell lung cancer (NSCLC)
accounting for 85% and has a low survival rate of 5 years. Dysregulation of microRNAs …

Abstract Introduction Brain metastases (BMs) occur in 40% of patients with lung cancer. The
activity of immunotherapy in these patients, however, remains controversial, as the …

Non–small cell lung cancer (NSCLC) is the most common tumor that metastasizes to the
brain. It is now accepted that the successful colonization and growth of tumor cells are …